183 related articles for article (PubMed ID: 19850637)
1. Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
Massard C; Zonierek J; Gross-Goupil M; Fizazi K; Szczylik C; Escudier B
Ann Oncol; 2010 May; 21(5):1027-31. PubMed ID: 19850637
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
3. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Raspollini MR
Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
[No Abstract] [Full Text] [Related]
4. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
Valcamonico F; Ferrari V; Amoroso V; Rangoni G; Simoncini E; Marpicati P; Vassalli L; Grisanti S; Marini G
J Neurooncol; 2009 Jan; 91(1):47-50. PubMed ID: 18712279
[TBL] [Abstract][Full Text] [Related]
5. Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Vanhuyse M; Penel N; Caty A; Fumagalli I; Alt M; Zini L; Adenis A
Bull Cancer; 2012 Dec; 99(12):100-6. PubMed ID: 23220100
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in advanced clear-cell renal-cell carcinoma.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Siebels M; Negrier S; Chevreau C; Solska E; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Freeman S; Schwartz B; Shan M; Simantov R; Bukowski RM;
N Engl J Med; 2007 Jan; 356(2):125-34. PubMed ID: 17215530
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib rechalenge in metastatic renal cell carcinoma.
Porta C; Paglino C; Imarisio I
BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
[No Abstract] [Full Text] [Related]
10. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
Bellmunt J; Maroto-Rey P; Trigo JM; Carles J; Guillem V; López-Martín JA; Antón-Torres A; Urruticoechea L
Clin Transl Oncol; 2010 Jul; 12(7):503-8. PubMed ID: 20615828
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib: in advanced renal cancer.
McKeage K; Wagstaff AJ
Drugs; 2007; 67(3):475-83; discussion 484-5. PubMed ID: 17335301
[TBL] [Abstract][Full Text] [Related]
12. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
Tamaskar I; Bukowski R; Elson P; Ioachimescu AG; Wood L; Dreicer R; Mekhail T; Garcia J; Rini BI
Ann Oncol; 2008 Feb; 19(2):265-8. PubMed ID: 17962201
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Lekili M; Muezzinoglu T; Nese N; Temeltas G
J Chin Med Assoc; 2010 May; 73(5):262-4. PubMed ID: 20685594
[TBL] [Abstract][Full Text] [Related]
14. [Myocardial metastasis from renal cell carcinoma treated with sorafenib].
Tokuyama Y; Iwamura M; Fujita T; Sugita A; Maeyama R; Bessho H; Ishikawa W; Tabata K; Yoshida K; Baba S
Hinyokika Kiyo; 2011 Oct; 57(10):555-8. PubMed ID: 22089153
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of a brain-metastasized renal cell carcinoma.
Walid MS; Johnston KW
Ger Med Sci; 2009 Oct; 7():Doc28. PubMed ID: 19911072
[TBL] [Abstract][Full Text] [Related]
16. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Rini B; Szczylik C; Tannir NM; Koralewski P; Tomczak P; Deptala A; Dirix LY; Fishman M; Ramlau R; Ravaud A; Rogowski W; Kracht K; Sun YN; Bass MB; Puhlmann M; Escudier B
Cancer; 2012 Dec; 118(24):6152-61. PubMed ID: 22692704
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
18. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA
AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750
[TBL] [Abstract][Full Text] [Related]
19. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
Beck J; Procopio G; Bajetta E; Keilholz U; Negrier S; Szczylik C; Bokemeyer C; Bracarda S; Richel DJ; Staehler M; Strauss UP; Mersmann S; Burock K; Escudier B
Ann Oncol; 2011 Aug; 22(8):1812-23. PubMed ID: 21324953
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
Eisen T; Oudard S; Szczylik C; Gravis G; Heinzer H; Middleton R; Cihon F; Anderson S; Shah S; Bukowski R; Escudier B;
J Natl Cancer Inst; 2008 Oct; 100(20):1454-63. PubMed ID: 18840822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
